Marker Therapeutics, Inc. (MRKR)

Over the past six months, Marker Therapeutics' stock has experienced notable movements, including a 69.90% increase over the past year as of April 9, 2026. In January 2026, the stock was up nearly 114% in three months. The company reported its Year-End 2025 results on March 18, 2026, highlighting clinical trial results and a manufacturing collaboration with Cellipont Bioservices. Marker Therapeutics presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference in February 2026. A Baylor College of Medicine pancreatic cancer study utilizing Marker Therapeutics' MAR-T Cell Technology was featured on "Good Morning America" in January 2026. The first patient was treated in its Phase 1 RAPID study for MT-401 on October 6, 2025, and the company last reported earnings on November 14, 2025, with shares gaining 3.5% the day after the announcement.

Demand for Marker Therapeutics' products and services is primarily driven by the progression of its clinical trials, regulatory approvals, and the medical need for effective cancer treatments, rather than seasonal fluctuations. Demand is influenced by clinical trial outcomes, advancements in oncology research, disease prevalence, and regulatory milestones.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company utilizes its proprietary Multi-Antigen Recognizing (MAR)-T cell technology to target multiple tumor-associated antigens. Key product candidates include MT-601, an autologous multiTAA-specific T cell product in Phase 1 trials for lymphoma and pancreatic cancer, and MT-401-OTS, an off-the-shelf product in Phase 1 trials initially targeting AML and MDS.

Marker Therapeutics is headquartered in Houston, Texas, United States, and its clinical trials include patients across multiple U.S. clinical sites.

Marker Therapeutics' brand reputation has been positively influenced by encouraging clinical trial results and scientific recognition, including positive response rates in the Phase 1 APOLLO study, positive pancreatic cancer data featured on "Good Morning America", a manufacturing collaboration with Cellipont Bioservices, the appointment of Kathryn Penkus Corzo to its Board of Directors, and the initiation of treatment in its off-the-shelf program (MT-401-OTS) with reported good tolerability. There is no readily available information suggesting significant negative events impacting Marker Therapeutics' reputation in the past year.

Marker Therapeutics has 39 institutional owners and shareholders, holding a total of 4,044,703 shares, including NEA Management Company, LLC, and Vanguard Group Inc. Individual insiders hold 7.42% of the shares, VC/PE Firms hold 9.75%, Institutions hold 14.5%, and the General Public holds 68.3%.